At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Mar 25, 2026 at 16:10 ET
Lifeward Ltd. has closed a strategic partnership with Oramed Pharmaceuticals, acquiring Oramed's clinical-stage Protein Oral Delivery (POD™) technology and securing access to up to $47 million in capital, of which $10 million was drawn on March 25, 2026. The deal transforms Lifeward into a diversified biomedical innovation company with expanded exposure to the biotech market.
- Lifeward acquired Oramed Pharmaceuticals' clinical-stage POD™ technology.
- The partnership provides Lifeward access to up to $47 million in capital.
- $10 million of capital was accessed on March 25, 2026.
- Lifeward has repositioned as a diversified biomedical innovation company.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access